Company Overview
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +284.46% |
| 6 Months: | +173.33% |
| 3 Months: | +156.71% |
| 1 Month: | +30.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCT Nuvectis Pharma, Inc. R2KPHARMA | 24.49 | -18.55 | $797.92M | 0.00% | -149.75% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -23.00K | -5.94M | -4.67M | -2.94M | -3.57M | -5.94M | -4.10M | -5.77M | -6.16M | -4.40M | -4.64M | -4.36M | -5.57M | -6.59M | -7.79M | -6.26M | -7.20M |
| Net Income | -23.00K | -5.94M | -4.67M | -2.94M | -3.57M | -5.88M | -4.05M | -5.71M | -5.88M | -4.17M | -4.43M | -4.15M | -5.33M | -6.33M | -7.46M | -6.05M | -7.02M |
| Diluted EPS | 0.01 | -1.43 | -1.04 | -0.32 | -0.28 | -0.42 | -0.27 | -0.38 | -0.37 | -0.25 | -0.26 | -0.24 | -0.27 | -0.30 | -0.44 | -0.26 | -0.30 |
| R&D Expense | - | 4.25M | 4.16M | 1.80M | 2.50M | 4.52M | 2.37M | 4.26M | 4.49M | 2.66M | 2.94M | 2.82M | 3.68M | 3.61M | 5.77M | 4.11M | 4.68M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -12.89M | -19.23M | -22.90M | -19.85M | -27.57M |
| Net Income | -12.89M | -19.09M | -22.26M | -19.00M | -26.44M |
| Diluted EPS | -3.02 | -1.51 | -1.43 | -1.11 | -1.32 |
| R&D Expense | 9.54M | 13.23M | 15.38M | 12.92M | 18.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 6.66M | 20.41M | 19.18M | 18.61M | 31.71M |
| Total Equity | -10.00K | -11.01M | 14.22M | 12.20M | 9.71M | 18.41M |
| Cash & Equivalents | - | 5.74M | 19.99M | 19.13M | 18.53M | 31.63M |
| Total Liabilities | - | 2.42M | 6.19M | 6.98M | 8.89M | 13.30M |
| Current Liabilities | - | 2.42M | 6.19M | 6.98M | 8.89M | 13.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -9.50M | -13.56M | -15.95M | -12.25M | -16.01M |
| Investing Cash Flow | - | 0 | 0 | 0 | - |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | 117.1% | -134.2% | -182.4% | -195.6% | -143.6% |
| ROCE % | -304.2% | -135.3% | -187.7% | -204.3% | -149.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 4.75% | 1.55M | $36.78M |
| 2 | Blackrock Inc. | 3.07% | 1.00M | $23.76M |
| 3 | Soleus Capital Management, L.P. | 3.06% | 1.00M | $23.73M |
| 4 | Perceptive Advisors Llc | 3.06% | 1.00M | $23.73M |
| 5 | Vanguard Capital Management LLC | 2.67% | 872.48K | $20.70M |
| 6 | Iridian Asset Management LLC | 2.38% | 777.08K | $18.44M |
| 7 | Geode Capital Management, LLC | 1.32% | 432.27K | $10.26M |
| 8 | Baldwin Wealth Partners LLC/MA | 1.17% | 382.01K | $9.07M |
| 9 | Sphera Funds Management Ltd. | 1.17% | 382.94K | $9.09M |
| 10 | Occam Crest Management LP | 1.09% | 357.15K | $8.48M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVCT
Nuvectis Pharma plans two September talks, both available online - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdGRLcDhYSHlfanNEa3FRTWc1di1hVHVMTGhpNDg5X3R4bmd2SnJ6U085Q3otam40cTA5UlBYWUNyNndiSE5EOHlBQUxqMkpEYjBOUFZEdlp4VU5aQUQtbGVNQ3lfOTc4WkdsLUNkbGxwRXJOODZSb3pfSk9KTUliTXNVZVBUTkRHYlVneE…
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNSWhEQzBMdVJyd1NRdkVVZ3FqYjc4dVNLX0d3S29GMHdwQ21JV2xOck5VSUQtRkZENTNoMzlHZ0xjSlh5OEg4VnVUalhydk1zMmFyTVM2d3BnRmJZUHNyZEEyQnJIVVRzUFhMX1F1endLaVVBWGd3bzI2dDBMQXBraXRNd01kR2o3SWMtMz…
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxONl9NQjExMEhYVWJ3SlM4ZTFqQWFBOVJ3Y1hnVU9jbGQtZWM4UmpDbkxxQnludTRnVFhuUUFQRGs1ZUJfenZXQ0g1aFdmVGVsNWN3SG1ObnNJN2IxazJGX0dwZzEwdzMzb3R0QmxWbGpsQ0oxcWYxMHlMTk1HQzZoLXQybGZvMlZHZkZfRE…
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - qz.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOZjZldXVuSDBwVXhGZ19ZczNUU3RBc05vTEpwelQ2UkktUzUzdThwTUd5Ym9ZQVg4cWtDZFBUal9iUjBGN3c3QUljeWkxV2Z6eGdkUFctcF84LUFPOE1oaUVBUUFEVHVLcHNrTGhtaEN4R0hZZDdOaGU4X1lBWmlNZHdzeTZkdGhWcTB6Yz…
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals | NVCT Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQZUVrcWNQVThldmEwNDhRdWtSVlVVeWJwLUN2V1dmOU1aaE1HaHBvN0hJd0pwMTFrM05Ka0lBZHFVbmhZQXRxUjdtbGRFNHdoMnhSUHFWUVNrejJZRktPbGoxVXhjWUcyd3BCeGF2ejF0RHBQdHJLeFJSVy1SRUNKLTFBc2pnSHhnNGV1eV…
Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending - Benzinga
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPd1hiUC12UERVWWpMcjNESUtoMUoyaUdJelI4S0VZNlVIVjNjWjROVU9MY3pyazVxZTRLXzZTdGdYRWNHUjFVSjVYeXJMZUY5RXhCMUN2MVlMZ2lBaXlBTkJzdVpMTkFCVXpxUGNFNUREVWQ4NUdXWFdxX3J5NUw3VEdWVHViS2xrZFdhdl…
NVCT — Frequently Asked Questions
What is the current share price of Nuvectis Pharma, Inc. (NVCT)?
As of 2026-09-07 16:24 PDT, Nuvectis Pharma, Inc. (NVCT) trades at $24.49 on NasdaqCM. Its 52-week range is $5.65 to $28.53.
What is the market capitalisation of NVCT?
Nuvectis Pharma, Inc. (NVCT) has a market capitalisation of $797.92M on NasdaqCM.
What is the P/E ratio of NVCT?
NVCT trades at a trailing price-to-earnings (P/E) ratio of -18.55. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 35.35.
Is NVCT a good stock to buy?
This page provides a data-driven analysis of Nuvectis Pharma, Inc. (NVCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.